ABSTRACT
OBJECTIVE: This study aimed to examine the value of Ki67 expression along with other potential prognostic factors for predicting overall survival and disease-free survival in patients with gastrointestinal stromal tumors who underwent curative resection. PATIENTS AND METHODS: Sixty-eight histologically confirmed and operated patients with gastrointestinal stromal tumors were included. Clinical and follow-up data were retrieved from medical records and patients were contacted at the end of the study. The effects of certain clinical and histopathological parameters on survival outcomes were examined. RESULTS: Sixty-eight patients were followed for a mean duration of follow-up of 2923.3 patient-months. Twelve deaths (17.6%), seven metastasis (10.3%), and two local recurrences (2.9%) occurred. Overall survival was 102.5 months [95% confidence interval (CI), 88.3-116.8] and disease-free survival was 91.8 months (95% CI, 76.5-107.2). Multivariate analyses identified a high Ki67 index (≥ 10%) as an independent predictor of both poor overall survival (hazard ratio, 4.8; 95% CI 1.2-19.2; P=0.027) and poor disease-free survival (hazard ratio, 15.3; 95% CI, 4.7-50.2). CONCLUSION: A high Ki67 expression seems to be a useful prognostic factor that would aid in predicting disease course in gastrointestinal stromal tumors. These findings deserve further investigation in larger studies.
Subject(s)
Gastrointestinal Neoplasms/chemistry , Gastrointestinal Neoplasms/surgery , Gastrointestinal Stromal Tumors/chemistry , Gastrointestinal Stromal Tumors/surgery , Ki-67 Antigen/analysis , Neoplasm Recurrence, Local/chemistry , Aged , Disease-Free Survival , Female , Follow-Up Studies , Gastrointestinal Neoplasms/pathology , Gastrointestinal Stromal Tumors/secondary , Humans , Male , Middle Aged , Mitotic Index , Survival Rate , Time Factors , Treatment OutcomeSubject(s)
Ampicillin/adverse effects , Liver/drug effects , Sulbactam/adverse effects , Female , Humans , Liver/injuries , Liver/pathology , Middle AgedSubject(s)
Foreign-Body Migration/surgery , Gastroplasty/adverse effects , Laparoscopy , Obesity, Morbid/surgery , Adult , Female , Gastroplasty/methods , Humans , ReoperationABSTRACT
Ectopic varices (EcV) accounting for 1-5% of all varices in portal hypertension are composed of dilated portosystemic collaterals located in unusual sites instead of the most known gastroesophageal region. The difficulty in localization of bleeding is a great burden on the management of these patients. Herein, we present patients with EcV as well as with portal hypertension and recurrent intestinal bleeding. The sites of EcV were identified with computed tomographic angiography, after a series of inconclusive endoscopies, and moreover a selective celiac arteriographic examination of one of the patients.
Subject(s)
Angiography/methods , Esophageal and Gastric Varices/diagnostic imaging , Gastrointestinal Hemorrhage/diagnostic imaging , Hypertension, Portal/complications , Tomography, X-Ray Computed/methods , Aged , Anticoagulants/therapeutic use , Blood Transfusion , Embolization, Therapeutic , Esophageal and Gastric Varices/etiology , Female , Gastrointestinal Hemorrhage/etiology , Heparin/therapeutic use , Humans , Portasystemic Shunt, Transjugular Intrahepatic , Treatment Outcome , Venous Thrombosis/diagnostic imaging , Venous Thrombosis/etiologyABSTRACT
BACKGROUND: Peroxisome proliferator-activated receptor alpha (PPARalpha) plays important roles in lipid metabolism. A recently discovered L162V polymorphism of the PPARalpha gene is associated with enhanced transcriptional activity. In this study, the frequency of L162V was investigated in nonalcoholic steatohepatitis (NASH) and genotype 1 hepatitis C virus (HCV)-related liver steatosis. METHODS: Seventy-two NASH and 141 HCV-infected patients (54 with steatosis, 87 without steatosis) and 119 healthy controls were included. L162V polymorphism of the PPARalpha gene was analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). RESULTS: PCR and RFLP analysis of the related gene segment was successful in 93%, 96%, and 100% of NASH and HCV-infected patients and controls, respectively. The frequency of the L162V polymorphism was similar in the NASH and HCV-infected patients and controls (5.9%, 3.6%, and 2.5%, respectively). No difference in the frequency of this polymorphism was observed in HCV-infected patients with or without significant liver steatosis. L162V was not associated with obesity, type 2 diabetes mellitus, hypercholesterolemia, or hypertriglyceridemia. CONCLUSIONS: Neither NASH nor genotype 1 HCV-related liver steatosis seems to be associated with the PPARalpha L162V polymorphism. This polymorphism may have no association with the presence of type 2 diabetes mellitus, obesity, or various blood lipid alterations in NASH and HCV-infected patients.